Entropy Neurodynamics Ltd (ASX:ENP) Share Price

Company Profile

Business description
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Contact
117 Camberwell Road,, Hawthorn East
Suite 1.01
Camberwell
MelbourneVIC3123
AUS
T: +61 390920475
https://www.tryptherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
50

Recommended

Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.

Rachel Schlueter | 06 March 2026

A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.

Tyger Fitzpatrick | 06 March 2026

How the most traded shares stack up against our analysts views.

Tyger Fitzpatrick | 04 March 2026

Index	Last price	Change	% Change
All Ordinaries	9,085.10	36.30	0.40%
CAC 40	7,966.78	200.95	-2.46%
DAX 40	23,572.22	243.53	-1.02%
Dow JONES (US)	47,954.74	784.67	-1.61%
FTSE 100	10,334.61	79.33	-0.76%
HKSE	25,768.40	447.06	1.77%
NASDAQ	22,748.99	58.50	-0.26%
Nikkei 225	55,620.84	342.78	0.62%
NZX 50 Index	13,519.35	98.54	-0.72%
S&P 500	6,830.71	38.79	-0.56%
S&P/ASX 200	8,851.00	25.80	0.29%
SSE Composite Index	4,124.19	15.63	0.38%